State Street My2028 Corporate Bond ETF (MYCH)
Live price chart, market sentiment, and community perspectives for State Street My2028 Corporate Bond ETF (NASDAQ: MYCH).
Live price chart, market sentiment, and community perspectives for State Street My2028 Corporate Bond ETF (NASDAQ: MYCH).
On our desk, we noticed that short interest in MYCH expanded significantly by 492.8% according to recent filings. While the fund trades steadily around the $24.80 level with a low 0.15% expense ratio, this massive spike in short positioning warrants a closer look at institutional hedging patterns or tactical arbitrage plays running up to the 2028 target maturity date.
When analyzing the quantitative profile of MYCH, the AGARCH volatility model parameter estimates reveal important structural dynamics. The leverage parameter (gamma = 0.10) shows that negative returns raise next-day volatility more aggressively than positive returns of equivalent size, meaning downside shocks require tighter risk parameters in portfolio overlays.
From a structural standpoint, investors need to remember that MYCH is designed to terminate and liquidate on or about December 15, 2028, distributing remaining assets. Since it does not guarantee a predetermined redemption amount, holding it as a held-to-maturity instrument carries underlying credit exposure tied strictly to its 2028 corporate bond basket.
As a portfolio manager evaluating the State Street MyIncome suite, MYCH offers clean structural utility for building custom bond ladder portfolios targeting 2028. However, market sentiment feels lukewarm, with Danelfin's AI scoring it a 4/10 'Hold' due to a slight negative probability advantage relative to the broader ETF universe over the next three months.
Watching the recent price action near $24.85 with modest daily volume around 52.3K shares, MYCH continues to trade like a typical target-date vehicle. The absence of an index tracking mandate means it relies purely on active top-down risk management and bottom-up security selection, which adds execution risk compared to passive benchmark trackers.
Explore plasma cleansing, somatic organ swaps, and BCI.